Logo image of DTIL

PRECISION BIOSCIENCES INC (DTIL) Stock Fundamental Analysis

NASDAQ:DTIL - Nasdaq - US74019P2074 - Common Stock - Currency: USD

5.13  -0.02 (-0.39%)

Fundamental Rating

3

Overall DTIL gets a fundamental rating of 3 out of 10. We evaluated DTIL against 563 industry peers in the Biotechnology industry. DTIL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DTIL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DTIL had negative earnings in the past year.
In the past year DTIL has reported a negative cash flow from operations.
In the past 5 years DTIL reported 4 times negative net income.
DTIL had a negative operating cash flow in each of the past 5 years.
DTIL Yearly Net Income VS EBIT VS OCF VS FCFDTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

With an excellent Return On Assets value of 5.25%, DTIL belongs to the best of the industry, outperforming 93.61% of the companies in the same industry.
DTIL's Return On Equity of 12.71% is amongst the best of the industry. DTIL outperforms 94.49% of its industry peers.
Industry RankSector Rank
ROA 5.25%
ROE 12.71%
ROIC N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
DTIL Yearly ROA, ROE, ROICDTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

With an excellent Profit Margin value of 10.43%, DTIL belongs to the best of the industry, outperforming 94.14% of the companies in the same industry.
DTIL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 10.43%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DTIL Yearly Profit, Operating, Gross MarginsDTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DTIL has been increased compared to 1 year ago.
DTIL has more shares outstanding than it did 5 years ago.
DTIL has a worse debt/assets ratio than last year.
DTIL Yearly Shares OutstandingDTIL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
DTIL Yearly Total Debt VS Total AssetsDTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.97, we must say that DTIL is in the distress zone and has some risk of bankruptcy.
DTIL has a Altman-Z score (-3.97) which is in line with its industry peers.
DTIL has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
DTIL has a Debt to Equity ratio of 0.40. This is in the lower half of the industry: DTIL underperforms 73.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -3.97
ROIC/WACCN/A
WACC10.26%
DTIL Yearly LT Debt VS Equity VS FCFDTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 6.34 indicates that DTIL has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.34, DTIL is doing good in the industry, outperforming 65.54% of the companies in the same industry.
DTIL has a Quick Ratio of 6.34. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.34, DTIL is in the better half of the industry, outperforming 66.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.34
Quick Ratio 6.34
DTIL Yearly Current Assets VS Current LiabilitesDTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

DTIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.07%, which is quite impressive.
DTIL shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.98%.
Measured over the past years, DTIL shows a very strong growth in Revenue. The Revenue has been growing by 25.30% on average per year.
EPS 1Y (TTM)99.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.32%
Revenue 1Y (TTM)40.98%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-90.93%

3.2 Future

DTIL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.21% yearly.
DTIL is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.96% yearly.
EPS Next Y-4238.4%
EPS Next 2Y-377.05%
EPS Next 3Y-166.5%
EPS Next 5Y59.21%
Revenue Next Year-69.62%
Revenue Next 2Y-37.11%
Revenue Next 3Y-24.32%
Revenue Next 5Y-4.96%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DTIL Yearly Revenue VS EstimatesDTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
DTIL Yearly EPS VS EstimatesDTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DTIL. In the last year negative earnings were reported.
Also next year DTIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DTIL Price Earnings VS Forward Price EarningsDTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DTIL Per share dataDTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

DTIL's earnings are expected to decrease with -166.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-377.05%
EPS Next 3Y-166.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DTIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECISION BIOSCIENCES INC

NASDAQ:DTIL (5/9/2025, 8:00:01 PM)

5.13

-0.02 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners50.49%
Inst Owner Change-1.16%
Ins Owners5.08%
Ins Owner Change0.99%
Market Cap54.12M
Analysts84
Price Target21.93 (327.49%)
Short Float %7.01%
Short Ratio3.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.8%
Min EPS beat(2)-14.74%
Max EPS beat(2)-10.86%
EPS beat(4)2
Avg EPS beat(4)115.17%
Min EPS beat(4)-14.74%
Max EPS beat(4)404.22%
EPS beat(8)5
Avg EPS beat(8)60.51%
EPS beat(12)7
Avg EPS beat(12)40.57%
EPS beat(16)10
Avg EPS beat(16)47.62%
Revenue beat(2)0
Avg Revenue beat(2)-88.24%
Min Revenue beat(2)-91.12%
Max Revenue beat(2)-85.37%
Revenue beat(4)2
Avg Revenue beat(4)115.56%
Min Revenue beat(4)-91.12%
Max Revenue beat(4)452.4%
Revenue beat(8)5
Avg Revenue beat(8)89.48%
Revenue beat(12)7
Avg Revenue beat(12)58.9%
Revenue beat(16)10
Avg Revenue beat(16)93.16%
PT rev (1m)11.36%
PT rev (3m)-27.08%
EPS NQ rev (1m)-351.75%
EPS NQ rev (3m)-351.75%
EPS NY rev (1m)-18.66%
EPS NY rev (3m)-18.66%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)9.69%
Revenue NY rev (3m)9.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.79
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-6.51
Fwd EYN/A
FCF(TTM)-5.57
FCFYN/A
OCF(TTM)-5.54
OCFYN/A
SpS6.51
BVpS5.35
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.25%
ROE 12.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.43%
GM N/A
FCFM N/A
ROA(3y)-26.66%
ROA(5y)-33.41%
ROE(3y)-165.71%
ROE(5y)-155.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.08%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.34
Quick Ratio 6.34
Altman-Z -3.97
F-Score5
WACC10.26%
ROIC/WACCN/A
Cap/Depr(3y)28.02%
Cap/Depr(5y)41.2%
Cap/Sales(3y)6.1%
Cap/Sales(5y)8.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.32%
EPS Next Y-4238.4%
EPS Next 2Y-377.05%
EPS Next 3Y-166.5%
EPS Next 5Y59.21%
Revenue 1Y (TTM)40.98%
Revenue growth 3Y-15.91%
Revenue growth 5Y25.3%
Sales Q2Q%-90.93%
Revenue Next Year-69.62%
Revenue Next 2Y-37.11%
Revenue Next 3Y-24.32%
Revenue Next 5Y-4.96%
EBIT growth 1Y40.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-100.82%
EBIT Next 3Y-6.79%
EBIT Next 5Y-11.5%
FCF growth 1Y32.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.52%
OCF growth 3YN/A
OCF growth 5YN/A